Merck (MRK) to acquire Terns (TERN) for USD 53/shr; deal valued at USD 6.7bln and expected to close in Q2 2026

Merck's acquisition of Terns for $6.7 billion at $53 per share indicates a significant strategic move, likely aimed at enhancing Merck's pipeline in pharmaceuticals and biotechnology. This deal, expected to close in Q2 2026, could potentially shift investor sentiment positively towards Merck, though investors will need to assess the implications for funding and integration risks moving forward.